Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company that regularly reports updates on its pipeline of seven programs targeting novel mechanisms of action for brain diseases and other underserved, prevalent diseases. News about Neumora often centers on clinical trial progress, preclinical data, financial results and corporate presentations, giving investors and observers insight into how its development strategy is unfolding.
Recent press releases highlight multiple areas of activity. The company has reported positive Phase 1b results for NMRA-511, an oral, highly potent, brain-penetrant and selective vasopressin 1a receptor antagonist being evaluated for agitation associated with Alzheimer’s disease. It has also provided frequent updates on navacaprant, a kappa opioid receptor antagonist in Phase 3 KOASTAL studies for major depressive disorder, including plans for consolidated topline readouts.
Neumora’s news flow also covers its M4 muscarinic receptor positive allosteric modulator franchise, with Phase 1 SAD/MAD studies of NMRA-861 and NMRA-898 designed to assess safety, tolerability and pharmacokinetics in healthy adults and people with stable schizophrenia. In addition, the company has announced preclinical diet-induced obesity data for NMRA-215, a highly brain-penetrant oral NLRP3 inhibitor prioritized for obesity, and has outlined plans to move this program into clinical testing.
Beyond scientific and clinical milestones, Neumora issues regular quarterly financial results, business updates and notices of participation in healthcare and investor conferences. The NMRA news page on Stock Titan aggregates these announcements so readers can follow developments in Alzheimer’s disease agitation, major depressive disorder, schizophrenia, obesity and other areas where Neumora is active.
Neumora Therapeutics (Nasdaq: NMRA) reported Q4 and full-year 2025 results and a business update on March 30, 2026. The company finished 2025 with $182.5 million in cash and expects runway into the third quarter of 2027.
Key clinical highlights: KOASTAL-2/-3 fully enrolled (>400 patients each) with joint topline readout expected in Q2 2026; NMRA-511 showed effect sizes of 0.34 (CMAI total) and 0.51 (CMAI aggression) in a 53-patient pre-specified AD agitation cohort; NMRA-898 selected as M4 lead with ~80–100 hour half-life; NMRA-215 toxicology signal under audit and clinical start now targeted Q1 2027.
Neumora Therapeutics (Nasdaq: NMRA) will report fourth quarter and full year 2025 financial results on Monday, March 30, 2026 and will host a conference call and live webcast at 8:00 a.m. ET.
According to Neumora Therapeutics, the live webcast will be available on the company website and a replay will be archived for up to 30 days. Participants are advised to register at least 10 minutes before the call.
Neumora Therapeutics (Nasdaq: NMRA) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York.
A live webcast will be available on the company’s events and presentations page and a replay will be archived for up to 30 days.
Neumora Therapeutics (NASDAQ: NMRA) outlined its 2026 pipeline strategy and key near-term milestones, highlighting multiple clinical readouts and program advances. The company expects a joint topline readout for KOASTAL-2 and KOASTAL-3 in Q2 2026 and plans to increase enrollment in each study by up to 25% beyond the original 332 target where protocols allow. Neumora plans to initiate a Phase 1 program for NMRA-215 in H1 2026 with weight-loss data expected around year-end 2026. The company reported positive Phase 1b results for NMRA-511 showing a clinically meaningful effect on AD agitation and no somnolence. Cash runway is expected into Q3 2027.
Neumora Therapeutics (NASDAQ: NMRA) reported positive Phase 1b signal-seeking results for NMRA-511 in Alzheimer’s disease agitation on Jan 5, 2026. Key findings: a reported 15.7-point mean reduction on CMAI total score, larger placebo-adjusted improvements in a pre-specified elevated-anxiety subgroup (placebo-adjusted -7.6 at Week 6, -5.6 at Week 8; Cohen’s d 0.51–0.64), and a favorable tolerability and safety profile with 2.5% discontinuations due to TEAEs. The study was a signal-seeking, not powered for statistical significance. Next steps: multiple ascending dose expansion and formulation work for once-daily extended-release dosing in 2026.
Neumora Therapeutics (NASDAQ: NMRA) reported third-quarter 2025 results and updated pipeline progress on Nov 6, 2025. The company holds $171.5M in cash, cash equivalents and marketable securities and says that funding is expected to support operations into 2027. Neumora drew an additional $40M of non-dilutive capital from its existing K2 HealthVentures facility.
Pipeline milestones: NMRA-215 (oral NLRP3 inhibitor) showed class-leading DIO mouse data and is expected to enter Phase 1 in Q1 2026 with 12-week PoC data in 2026; two M4 PAMs (NMRA-861, NMRA-898) are in Phase 1 with a franchise update planned mid-2026; NMRA-511 Phase 1b data for AD agitation is on track around year-end; navacaprant KOASTAL topline readouts expected in Q1 and Q2 2026.
Neumora Therapeutics (Nasdaq: NMRA) will participate in two investor conferences in November 2025. Management will take part in fireside chats at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 2:30 p.m. ET in Boston and at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:00 p.m. ET in New York.
A live webcast of both events will be available on the company's events and presentations webpage at www.neumoratx.com, with replays archived for up to 30 days after the events.
Neumora Therapeutics (Nasdaq: NMRA) initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898 on Oct 27, 2025.
NMRA-898 is a structurally distinct second M4 muscarinic receptor positive allosteric modulator (PAM) alongside NMRA-861. Both programs aim for once-daily dosing and central nervous system exposure to treat schizophrenia and other neuropsychiatric disorders. Preclinical studies reported no convulsions across multiple species, including rabbits. The company will evaluate Phase 1 safety, tolerability, and human PK to decide whether to advance one or both programs and expects a comprehensive M4 franchise update by mid-2026.
Neumora Therapeutics (Nasdaq: NMRA) reported positive preclinical results for NMRA-215, an oral, brain-penetrant NLRP3 inhibitor for obesity. In three diet-induced obesity mouse studies, NMRA-215 produced up to 19% weight loss as a monotherapy and up to 26% weight loss in combination with semaglutide. The company plans to initiate a Phase 1 clinical study in Q1 2026. Additional data will be presented during a virtual R&D day on October 27, 2025 with a webcast and 30-day replay.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, will host a virtual R&D Day on October 27, 2025, at 8:00 a.m. ET. The event will showcase the company's pipeline of seven programs targeting novel mechanisms for prevalent diseases.
Key presentations will feature NMRA-215, a brain-penetrant NLRP3 inhibitor for obesity treatment, NMRA-511 Phase 1b data for Alzheimer's agitation, the M4 franchise (NMRA-861 and NMRA-898), and navacaprant, a Phase 3 kappa opioid receptor antagonist.